Internal Medicine, Hematology & Oncology · Lexington, KY
NPI
1578940680
Since 2015
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
University of Kentucky, 800 Rose Street
Lexington, KY, 40536
Phone (816) 404-4862
Groups this clinician bills Medicare through
Medicare paid, 2024
$38K
380 services
Medicare patients, 2024
117
Average age 68
Drug cost, 2024
$6.1M
1,479 prescriptions
Company payments, 2025
$8,504
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ayman Qasrawi was code 99233 (hospital e&m - subsequent), 170 times for 40 patients. In total Ayman Qasrawi billed 380 services in 18 codes, and Medicare paid $38K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-03-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 170 | 40 | $95.74 | $16K |
| 99215 Office E&M - Established | Facility | 99 | 41 | $112.85 | $11K |
| 99214 Office E&M - Established | Facility | 31 | 25 | $69.45 | $2,153 |
| 99223 Hospital E&M - Initial | Facility | 29 | 24 | $139.78 | $4,054 |
By year: 2022 $33K for 373 services; 2023 $34K for 394 services; 2024 $38K for 380 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ayman Qasrawi prescribed most often to Medicare patients was Acyclovir, with 164 prescriptions and refills. In total Ayman Qasrawi wrote 1,479 Medicare prescriptions that cost $6.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 164 | 209 | 47 | $2,814 |
| Venclexta Venetoclax | 99 | 99 | 23 | $278K |
| Posaconazole Generic | 89 | 89 | 23 | $90K |
| Fluconazole Generic | 70 | 71 | 25 | $3,843 |
| Levofloxacin Generic | 63 | 67 | 20 | $630 |
| Rezurock Belumosudil Mesylate | 49 | 49 | Under 11 | $1.3M |
| Gabapentin Generic | 38 | 48 | Under 11 | $200 |
| Cefdinir Generic | 38 | 43 | Under 11 | $1,425 |
| Oxycodone Hcl Generic | 35 | 35 | 16 | $530 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 35 | 41 | Under 11 | $76.27 |
| Pantoprazole Sodium Generic | 31 | 39 | Under 11 | $134 |
| Promacta Eltrombopag Olamine | 31 | 31 | Under 11 | $594K |
| Jakafi Ruxolitinib Phosphate | 29 | 29 | Under 11 | $450K |
| Prochlorperazine Maleate Generic | 29 | 29 | 24 | $384 |
| Ondansetron Odt Ondansetron | 28 | 28 | Under 11 | $2,280 |
Brand drugs: 458 claims; generic drugs: 1,021 claims; opioid claims: 63.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ayman Qasrawi $8,504 ($8,504 in general payments such as food, travel and fees) from 5 companies. The largest payer was Genzyme Corporation with $8,362.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.